Pear Therapeutics, Inc. will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9th at 10:30 a.m. at the InterContinental Boston.
Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions.
About Pear Therapeutics
At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Our lead product, reSET®, treats Substance Use Disorder, and was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product candidate, reSET-O™ for the treatment of Opioid Use Disorder, is currently under review by the FDA with Breakthrough Designation. For more information, visit us at www.peartherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180731005172/en/
Contacts
Media and Investors:
Pear Therapeutics
Amanda Galgay
corporatecommunications@peartherapeutics.com
Source: Pear Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20180731005172/en
